UK QPPV Requirements

An expanded, inspection‑ready reference on the statutory and practical requirements for UK Qualified Persons Responsible for Pharmacovigilance (UK QPPVs), suitable for inclusion in a corporate pharmacovigilance governance library.

This document sets out the statutory context, detailed duties and availability expectations, PSMF content and location considerations, governance implications and a practical inspection‑readiness checklist.

Table of Contents

• Statutory and regulatory context
• When is a UK QPPV required?
• Detailed UK QPPV duties and responsibilities
• Core responsibilities
• Safety data and reporting
• Signal management and risk assessment
• Risk management plans and safety strategy
• Quality systems and governance
• Outsourcing, vendors and contracts
• Records, systems and confidentiality
• Inspections and corrective actions
• Delegation and documentation
• Professional qualifications and competence
• UK QPPV availability and deputy arrangements — practical implementation
• Regulatory expectation
• Practical, inspection‑oriented availability measures
• Delegation governance
• Inspection relevance
• PSMF (Pharmacovigilance System Master File): content, location and implementation
• Regulatory role of the PSMF
• Location and accessibility
• Implementation details
• Inspection relevance
• Governance and organisational considerations
• Governance model
• KPIs and oversight
• Budget and resourcing
• Change control and compliance assurance
• Legal and contractual accountability
• Inspection‑readiness checklist (operational, for immediate use)
• Practical pre‑inspection steps (recommended as part of the checklist)
• Practical tips for maintaining inspection readiness
• Inspection relevance and likely inspector focus areas
• Conclusion
• References
• Regulatory Note

Statutory and regulatory context

• Statutory basis: Pharmacovigilance obligations in the UK are established by the Human Medicines Regulations 2012 (SI 2012/1916), as amended (the HMR 2012). These regulations place legal obligations on Marketing Authorisation Holders (MAHs) to establish and maintain a pharmacovigilance system and to ensure appropriate monitoring and reporting of adverse reactions. The HMR 2012 provide the underpinning legal framework for MHRA oversight and inspection of pharmacovigilance systems.
• Regulatory guidance: The Medicines and Healthcare products Regulatory Agency (MHRA) publishes guidance on pharmacovigilance, including its public-facing guidance "Pharmacovigilance and reporting adverse reactions" and series guidance that aligns with Good Pharmacovigilance Practice (GVP) principles adopted in the UK. The MHRA expects MAHs to apply GVP principles adapted to the UK regulatory environment and to maintain documentation such as the Pharmacovigilance System Master File (PSMF).
• Inspection framework: The MHRA inspects pharmacovigilance systems under its statutory remit and evaluates compliance against the HMR 2012 and MHRA guidance. Inspectors will examine governance, organisational arrangements, QPPV responsibilities, PSMF content and accessibility, SOPs and records that demonstrate ongoing compliance.

(References and links to relevant MHRA guidance should be maintained in the corporate regulatory library and cited in inspection responses.)

When is a UK QPPV required?

• For all UK marketing authorisations, regulation 182 of the Human Medicines Regulations 2012 requires the MAH to have permanently and continuously at its disposal a QPPV responsible for establishment and maintenance of the pharmacovigilance system. Current MHRA guidance permits that QPPV to reside and operate in the UK or EU/EEA; if the QPPV is outside the UK, a UK-resident national contact person for pharmacovigilance is required.
• Presence of a UK QPPV is expected for MAHs holding UK marketing authorisations, including national and UK‑only authorised products and centrally authorised products placed on the UK market under appropriate arrangements.
• MAHs should document the legal/regulatory basis for appointing a QPPV in the PSMF and in the corporate governance framework (see PSMF section).

Detailed UK QPPV duties and responsibilities

The following is a comprehensive list of duties that an MAH should assign to the UK QPPV. Each duty should be set out in a formal job description, appointment letter, and be reflected in the PSMF and SOPs. Where duties are delegated, delegation must be documented and retained in the PSMF.

Core responsibilities

• Overall responsibility for establishing and maintaining the MAH's pharmacovigilance system for UK‑authorised products, ensuring compliance with HMR 2012 and MHRA guidance.
• Act as the single accountable UK pharmacovigilance point of contact for the MHRA and for other UK competent authorities where relevant.
• Maintain sufficient overview and knowledge of all safety data for UK products so that potential public health concerns can be rapidly identified and escalated.

Safety data and reporting

• Ensure timely collection, processing and reporting of adverse reaction reports (serious and non-serious) for UK‑authorised products in line with legal timeframes and MHRA requirements.
• Authorise and ensure submission of expedited reports and periodic reports (e.g., PBRERs/PSURs) as required for UK‑authorised products.
• Ensure submission or availability of CIOMS narratives, aggregate analyses and other documentation during inspections or at MHRA request.

Signal management and risk assessment

• Oversee signal detection, evaluation and management activities for UK‑authorised products. Maintain oversight of signal proposals, signal validation, prioritisation and assessment records.
• Ensure proposals for risk‑minimisation actions (including urgent safety restrictions, DHPCs or changes to product information) are developed in collaboration with regulatory affairs and medical affairs and are implemented and communicated appropriately.

Risk management plans and safety strategy

• Ensure the MAH maintains an up‑to‑date UK RMP (or appropriate risk management documentation) and that risk‑minimisation measures are implemented and monitored.
• Maintain and oversee safety surveillance plans and post‑authorisation safety studies relevant to UK products.

Quality systems and governance

• Ensure pharmacovigilance SOPs are current, accessible and applied, and that change control over SOPs is maintained.
• Ensure a documented quality management system (QMS) for pharmacovigilance, including audits, CAPAs, metrics, training and supplier oversight.
• Chair or provide executive sponsorship for pharmacovigilance governance bodies (e.g., PV Steering Committee), escalate issues to senior management and ensure appropriate resourcing.

Outsourcing, vendors and contracts

• Oversee pharmacovigilance service providers and ensure contractual arrangements (PVAs, SLAs) are in place, and that delegated tasks are adequately monitored and audited.
• Ensure vendor oversight includes evidence of data handling, service levels, access to safety databases and access for regulatory inspection.

Records, systems and confidentiality

• Ensure the integrity, security and accessibility of safety databases and records relevant to UK products.
• Ensure data protection and confidentiality requirements are applied in PV processes consistent with UK law and corporate policies.

Inspections and corrective actions

• Lead inspection preparedness, act as the company contact during MHRA inspections related to pharmacovigilance, and ensure timely implementation and verification of corrective and preventive actions (CAPAs).
• Maintain an inspection history file with previous inspection reports, CAPA status and evidence of closure.

Delegation and documentation

• Maintain a comprehensive record of delegations and functional responsibilities (who does what), with associated SOPs and contracts. Delegations must be explicit, time‑bound and reversible.

Professional qualifications and competence

• The UK QPPV should have appropriate scientific and pharmacovigilance qualifications and experience, documented in a CV maintained in the PSMF.
• Ensure continuing professional development and training records are maintained and auditable.

Each of the duties above should be traceable to governance documents, SOPs, training records, and PSMF sections that an inspector can review.

UK QPPV availability and deputy arrangements — practical implementation

Regulatory expectation

• The MHRA expects the UK QPPV to be "permanently and continuously at the disposal" of the MAH to enable the MAH to meet its pharmacovigilance obligations. In practice this requires arrangements that ensure the QPPV can be contacted and can exercise responsibility on short notice for safety issues affecting UK products.

Practical, inspection‑oriented availability measures

• Appointment letter and job description: Include an explicit clause describing availability expectations, escalation routes and how the QPPV will be contacted in urgent situations. Retain signed appointment documentation in the PSMF.
• Deputies and escalation chain: Maintain a documented deputy roster that identifies named deputies (with job titles, contact details, delegation letters, and an order of succession). Deputies must have documented competencies and authority limits.
• On‑call rotas and contactability: Implement a two‑tier on‑call system for out‑of‑hours responses: (1) a primary UK QPPV contact for urgent safety issues and regulator requests, and (2) a named deputy for primary absence. Log on‑call schedules and ensure coverage 24/7 for serious safety events. Retain on‑call logs and call records for inspection.
• SLAs and internal policies: Document availability SLAs in the PV governance framework and in contracts with affiliates and service providers (e.g., 24‑hour acknowledgement for life‑threatening safety signals). Ensure SLAs are measurable, audited and included in the PSMF.
• Evidence of availability: Maintain contemporaneous evidence that the QPPV met availability expectations (phone logs, email timestamps, meeting minutes, decisions made in an out‑of‑hours context). These records are routinely requested during inspections.
• Business continuity plans (BCP): Maintain and test BCPs specific to the QPPV role and to key PV systems. BCPs should describe how continuity of QPPV functions is preserved during planned absence, illness, cyber incidents or other disruptive events. Test results and lessons learned should be retained for inspection.

Delegation governance

• All delegations should be supported by a written delegation of authority, competency assessments, training and monitoring arrangements. Delegations should be time‑limited and subject to review.
• The PSMF should contain a delegations matrix showing which pharmacovigilance tasks are delegated, to whom, and where evidence of oversight and monitoring is kept.

Inspection relevance

• Inspectors will expect to see evidence that the QPPV was available when required, deputisation arrangements worked in practice, and that urgent regulatory notifications were made without delay. Logs, escalation records and evidence of implemented CAPAs are the primary means to demonstrate compliance.

PSMF (Pharmacovigilance System Master File): content, location and implementation

Regulatory role of the PSMF

• The PSMF is the primary document that describes the MAH’s pharmacovigilance system. It is a key inspection document and should accurately reflect the current organisational arrangements, procedures, systems, resources and responsibilities (including UK QPPV details).
• The MHRA expects the PSMF to be readily available and to accurately describe the PV system for UK‑authorised products.

Minimum content and structure (inspection‑ready table of contents) Include at minimum the following sections and ensure each item is current, dated and supported by source documents:

1. Administrative information
2. MAH name, legal entity details and UK contact information
3. Statement of scope of the PSMF (which products and territories are covered)

4. Version control, document owner, review schedule

5. Organisational structure and responsibilities

6. Organogram showing PV organisation and interfaces with medical affairs, regulatory affairs, quality, clinical and commercial functions
7. UK QPPV: name, appointment letter, signed acceptance, functional job description, CV and contact details

8. List of designated deputies and escalation chain with documented delegations

9. PV system description and processes

10. Summary description of PV processes (case processing, signal management, aggregate reporting, RMP management, post‑authorisation studies)

11. Location and access details for electronic systems (safety database, e‑mail, document management, quality management system)

12. Product portfolio and regulatory status

13. Complete list of UK‑authorised products covered by the PSMF, including MA numbers, active substances, marketing authorisation dates, status and local product information links

14. Pharmacovigilance documents and SOPs

15. Index of PV SOPs and work instructions, including effective dates and change history

16. Copies or links to key SOPs (case processing, expedited reporting, signal management, PBRER preparation, PV audits, vendor oversight)

17. Safety database and IT systems

18. Details of the safety database (vendor, version, configuration, access controls)

19. Backup and retention policy, access log procedures, audit trail management

20. Contracts and outsourced activities

21. PV Agreements, SLAs, PVA templates, list of outsourced providers, evidence of oversight and audits

22. For delegated functions, include evidence that the MAH retains ultimate responsibility

23. Aggregate reporting and signal management

24. PBRER/PSUR calendar and submission history for UK products

25. Signal management policy, signal log extract for the last 3–5 years

26. Risk management

27. RMPs or UK risk documentation, risk‑minimisation measures, effectiveness monitoring plans and results

28. Quality system documentation

    • PV audit plan, audit reports, CAPAs, training records, PV metrics and performance indicators

29. Training and personnel records

    • Training matrix for PV personnel, evidence of QPPV and deputies’ training and CPD

30. Inspection history and correspondence

    • Copies of previous MHRA (or other) inspection reports, responses, CAPAs and closure evidence

31. Business continuity

    • BCPs relevant to PV and QPPV functions, test plans and results

32. Local UK annex (if global PSMF exists)

    • A distinct UK annex or chapter that summarises UK‑specific arrangements (UK QPPV appointment, UK product list, UK RMPs, UK contact details, PSMF storage and access arrangements)

Location and accessibility

• The PSMF should be readily accessible to the MHRA upon request and during inspection. Practical implementation options:
• Maintain a primary PSMF (electronic) on a secure document management system with the UK annex set as a distinct, easily exported subset.
• Ensure offline or downloadable packaged versions (PDF) can be produced quickly for inspection teams.
• Clearly indicate the physical or electronic location(s) of underpinning documentation (e.g., where contracts, database backups, and personnel records are stored).
• Evidence of access: maintain access logs, export logs and a record of PSMF distribution to internal stakeholders. Inspectors will validate that the PSMF is current and that the MAH can produce it promptly.

Implementation details

• PSMF owner and review: designate an accountable PSMF owner (often the UK QPPV or named PV lead) with a documented annual review schedule and version control.
• Cross‑linking: ensure PSMF cross‑references to SOPs, contracts, safety database extracts, and evidence repositories are valid and actively maintained.
• Localisation: if the company uses a global PSMF, include a UK annex that is standalone for inspection purposes. The UK annex should allow inspectors to find UK‑specific arrangements without sifting through global content.

Inspection relevance

• Inspectors will seek to verify QPPV appointment and availability details, delegation records, SOPs, safety database configuration, submission history and evidence of oversight. A complete, current and readily exportable PSMF is one of the single most important items an inspector will request.

Governance and organisational considerations

Governance model

• The QPPV role must be embedded in the corporate governance framework with clear lines of accountability to senior management or the board. The MAH should document:
• Who in senior management is accountable for PV resourcing and compliance
• How PV risks are escalated (risk register entries, reporting cadence)
• Frequency and membership of PV governance meetings (PV committee or equivalent)

KPIs and oversight

• Define and monitor KPIs that demonstrate PV system performance (timeliness of expedited reporting, case processing turnaround times, audit completion rate, CAPA closure timeliness, training completion).
• Use KPIs to inform board‑level reporting and to demonstrate to inspectors that the MAH actively measures and manages PV system performance.

Budget and resourcing

• Document budgetary decisions that support PV activities (e.g., funding for safety databases, vendor audits, training). Inspectors may ask how PV activities are resourced.

Change control and compliance assurance

• Ensure a documented change control process for PV systems, SOPs, and personnel changes (including succession planning for the QPPV). Maintain evidence of impact assessments and validation when changes touch safety systems.

Legal and contractual accountability

• Maintain legal documentation that makes clear that the MAH retains legal responsibility for PV even when functions are outsourced. Contractual clauses should reflect regulatory expectations for availability, access and inspection.

Inspection‑readiness checklist (operational, for immediate use)

Keep this checklist as a living document; update before every inspection or planned MHRA engagement. Store evidence items in a dedicated inspection pack linked to the PSMF.

A. Core documentation (must be current and exportable) - [ ] Current PSMF with UK annex and version control log. - [ ] UK QPPV appointment letter, signed acceptance, job description and up‑to‑date CV. - [ ] Delegation of authority matrix showing deputies and delegated functions (with delegation letters). - [ ] Complete list of UK‑authorised products covered by the PSMF (MA numbers and status). - [ ] Up‑to‑date organogram showing PV structure and interfaces. - [ ] Inventory and location (URLs/paths) of key PV SOPs and work instructions.

B. Availability and contactability evidence - [ ] On‑call rotas / on‑call schedule (last 12 months) with documented coverage. - [ ] Contact details (phone, mobile, email) and escalation chain. - [ ] Availability SLAs and internal policy describing QPPV availability expectations. - [ ] Evidence (call logs, emails, meeting minutes) of QPPV involvement in urgent safety decisions in the past 24 months.

C. Safety data and database - [ ] Safety database details (vendor, version, system owner, configuration documentation). - [ ] Case processing logs and sample case files showing triage, causality assessment, and reporting timelines. - [ ] Expedited report and aggregate report submission history for UK products. - [ ] Audit trails demonstrating data entry and modification controls.

D. Signal, risk management and aggregate reporting - [ ] Signal management policy and signal log extracts (recent signals and outcome records). - [ ] PBRER/PSUR submission calendar and recent submissions or status notes. - [ ] UK RMPs and documentation demonstrating implementation of risk‑minimisation measures.

E. Contracts and vendors - [ ] PVAs, SLAs and contracts with third‑party service providers. - [ ] Evidence of vendor oversight (audit reports, management reviews, KPI monitoring). - [ ] Data exchange agreements and data privacy compliance evidence.

F. Quality management and training - [ ] PV audit plan and recent audit reports (internal and vendor audits) with CAPA logs and evidence of closure. - [ ] Training matrix and records for QPPV, deputies and PV staff. - [ ] PV metrics and monthly/quarterly PV governance reports to senior management.

G. Business continuity and succession - [ ] QPPV BCP and testing records (including test results and lessons learned). - [ ] Succession plan for the QPPV role and evidence of deputy competency assessments.

H. Inspections and corrective actions - [ ] Past MHRA inspection reports, MAH responses and evidence of CAPA completion. - [ ] Inspection management plan (roles, responsibilities, on‑site logistics, document pull list). - [ ] Contact list for inspection team (internal and external support).

I. Governance and evidence of board oversight - [ ] PV governance committee minutes and evidence of escalation to senior management. - [ ] Board papers or executive summaries referencing PV risks and resourcing decisions.

Practical pre‑inspection steps (recommended as part of the checklist)

• [ ] Produce a current, exportable PSMF PDF and UK annex package and validate links.
• [ ] Prepare an inspection pack with core evidence items (A–I above) and a quick‑reference index.
• [ ] Ensure the QPPV and deputies have inspection briefings and are available for the inspection window.
• [ ] Assign a single inspection coordinator and record contact details in the inspection plan.

Practical tips for maintaining inspection readiness

• Keep the PSMF up to date with a named owner and scheduled reviews (at a documented risk-based interval or after significant change).
• Maintain a single source of truth for QPPV records (appointment letter, CV, delegations) and ensure physical or electronic signatures are archived.
• Use an internal audit calendar to validate availability and deputation arrangements annually.
• Store evidence of urgent decision‑making in a dedicated folder with timestamps to demonstrate responsiveness.
• Periodically simulate MHRA requests for PSMF material and measure the time to produce a complete package; use results to improve processes.

Inspection relevance and likely inspector focus areas

During an MHRA pharmacovigilance inspection, the inspector will typically: - Verify the legal and practical appointment of the UK QPPV and assess availability/deputy arrangements. - Review the PSMF for accuracy, completeness and evidence of ownership and review. - Examine SOPs, case processing files, safety database configuration, signal management records and aggregate reporting. - Evaluate governance, quality assurance (audits and CAPAs) and vendor oversight. - Test business continuity arrangements and evidence of continuity for the QPPV’s functions. - Inspectors will expect documentary evidence (signed appointment letters, delegation records, logs, audit reports, CAPAs, training records and PSMF extracts) to support assertions made by the MAH.

Conclusion

The UK QPPV is a legally and operationally pivotal role for MAHs with UK‑authorised products. Compliance requires clear statutory understanding, robust governance and demonstrable operational practices: documented appointment and availability, a complete and current PSMF, tested continuity plans, explicit delegations, active governance and readiness to provide evidence during MHRA inspections. This page provides the practical, inspection‑focused content that MAHs should incorporate into their pharmacovigilance governance libraries.

• MHRA: Pharmacovigilance and reporting adverse reactions — guidance and expectations for MAHs and QPPVs.
• MHRA publications on Good Pharmacovigilance Practice adapted for the UK — see MHRA website for current GVP‑aligned guidance and PSMF expectations.

Last reviewed: June 2026

References

• Human Medicines Regulations 2012 (SI 2012/1916), as amended — statutory framework for medicines regulation in the UK.

Regulatory Note

This article is educational. Binding obligations arise from applicable legislation and marketing-authorisation conditions. GVP and national-authority publications describe regulatory expectations. Suggested models, frequencies, thresholds, scorecards, matrices, checklists and scenarios are illustrative or recommended practice unless a legal provision is expressly identified.

Commission Implementing Regulation (EU) No 520/2012 was amended; use the consolidated text applicable from 12 February 2026 with current guidance. EMA states that affected GVP modules will be revised. Verify current legislation, guidance, national requirements, contracts and product-specific commitments before operational use.